Ebola is now a treatable disease.
Two of four experimental drugs designed to tackle Ebola have proven highly effective during field testing. Up until now, 70% infected of those infected with the Ebola virus have died. With the new drugs in play, 90% of those treated have been completely cured of the disease.
One of the drugs, REGN-EB3, is a cocktail of three monoclonal antibodies against Ebola made by Regeneron Pharmaceuticals of Tarrytown, New York. The second, mAB114, is derived from a single antibody recovered from the blood of a person who survived Ebola in the DRC in 1995 , and was developed by the US National Institute of Allergy and Infectious Diseases (NIAID).
Both drugs outperformed two other experimental treatments in the unprecedented multi-drug clinical trial in the DRC, the World Health Organization, INRB and NIAID said in a joint statement on 12 August. Preliminary data from the first 499 people enrolled in the study show that 29% of people given REGN-EB3 died, compared with 34% of those who received mAb114.
In order for these treatments to work, its important that a patient receive REGN-EB3 or mAB114 shortly after they were initially infected with Ebola. This could present a problem, however, given that an individual can have the virus coursing through their veins for days without showing any symptoms. Still, it's a wonderful start.
Now the trick is to figure out through—you guessed it—more trials, which of the these two drugs are the most effective in destroying the Ebola virus.
Image via CDC Global
Between 2010 and 2016, the FDA approved 210 new medicines and every single one was produced at public expense, part of a $1T US government investment project in medical research. Despite this massive public subsidy, the pharma industry has only grown more concentrated and rapacious, raising prices and diverting the profits to their execs and […]
Approximately 14 percent of the world’s population suffer from dry eye disease (DED) but treatments are limited because it’s difficult to model the complex human eye for drug development. Now though, University of Pennsylvania bioengineers developed an “eye-on-a-chip” complete with a motorized blinking eyelid. The hope is that the artificial eye will lead to a […]
In Chennai, India, a 7-year-old boy went to the hospital with a swollen jaw and mouth pain. Turned out he had more than 500 extra teeth. According to Prathiba Ramani, the head of Oral and Maxillofacial Pathology at Saveetha Dental College and Hospital, the teeth were contained in a sac tucked inside his lower jaw. […]
Breaking into the big leagues as a project manager isn’t done overnight, but there are principles that anyone can learn, and they’re applicable to nearly any business. No matter what your field, if there are multiple teams working toward a common goal, you’re going to need a roadmap. The Project Management Professional Certification Training Suite […]
On the one hand, nostalgia is “a corruption of the historical impulse,” according to William Gibson. On the other hand, “Super Mario Bros.” will never not be cool. Luckily, there’s a way to satisfy that retro gaming while still keeping an eye on the future: The GameShell Kit. This thing is simultaneously the last handheld […]
The field of data analytics can get intimidating, even for business professionals who constantly rely on it. But at its heart, its purpose is to simplify. To take mounds of information and distill their insights into a single clear picture. Currently, the go-to software for painting that picture is Tableau. And if you want to […]